BPL-003 Efficacy and Safety in Treatment Resistant Depression

Last updated: April 17, 2025
Sponsor: Beckley Psytech Limited
Overall Status: Active - Not Recruiting

Phase

2

Condition

Depression

Treatment

BPL-003

Clinical Study ID

NCT05870540
BPL-003-201
  • Ages 18-75
  • All Genders

Study Summary

This is a Phase 2 study randomized, quadruple masked, multi-center study , with a Open Label Extension, designed to investigate the efficacy and safety of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. At least moderate major depressive disorder.

  2. Diagnosed with TRD defined as failure to respond to an adequate dose and duration ofat least 2 pharmacological treatments based on the MGH ATRQ assessment.

  3. Hamilton Depression Rating Scale score ≥19 at Screening and Baseline.

  4. CGI-S ≥4 at Screening and Baseline.

  5. If currently taking antidepressant medications, willing and able to discontinuecurrent antidepressants.

Exclusion

Exclusion Criteria:

  1. Current or past history of schizophrenia, psychotic disorder including psychoticdepression, bipolar disorder, delusional disorder, schizoaffective disorder, or anyother severe psychiatric disorder.

  2. Current personality disorders.

  3. First-degree family history of schizophrenia, bipolar disorder, delusional disorder,or schizoaffective disorder.

  4. Current alcohol or substance use disorder (other than caffeine or nicotine).

  5. A participant who at any time has been unresponsive to ketamine, esketamine, anadequate course of treatment with electroconvulsive therapy, or has received vagalnerve stimulation or deep brain stimulation.

  6. Suicidal ideation or behavior within the 12 months prior to the start of Screeningor on Day 1 prior to dosing.

  7. Suicide attempt and/or self-injurious behavior within the last 12 months prior toScreening.

  8. Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure.

  9. History or current uncontrolled hypertension.

  10. Seizure disorder or any seizure in the 2 years prior to Screening.

  11. Has clinically significant results on ECG during the Screening.

  12. Any nasal obstruction, blockage, or symptoms of congestion at the time of dosingthat in the investigator's opinion may interfere with the administration of thestudy medication.

  13. Female participants who are pregnant, lactating, or of childbearing potential andnot willing to use adequate forms of contraception during the study.

  14. Male participants who are sexually active and not willing to use adequate forms ofcontraception during the study.

Study Design

Total Participants: 196
Treatment Group(s): 1
Primary Treatment: BPL-003
Phase: 2
Study Start date:
September 14, 2023
Estimated Completion Date:
June 30, 2025

Study Description

Approximately 200 eligible participants will receive a single dose of either low, medium, or high doses of BPL-003, given intranasally, with 8 weeks of follow up assessments. Following this participants may receive a second dose of either monophasic or biphasic dose of BPL-003, given intranasally, with another 8 weeks of follow up assessments.

Psychological support will be given before, during and after each dosing.

Connect with a study center

  • Royal Prince Alfred Hospital

    Sydney, New South Wales 2050
    Australia

    Site Not Available

  • University of Sydney

    Sydney, New South Wales 2050
    Australia

    Active - Recruiting

  • Dept. of Psychiatry and School Psychological Sciences, Monash University

    Clayton, Victoria 3168
    Australia

    Site Not Available

  • Monash University

    Clayton, Victoria 3168
    Australia

    Active - Recruiting

  • NeuroCentrix Research

    Melbourne, 3053
    Australia

    Site Not Available

  • Royal Melbourne Hospital, University of Melbourne

    Parkville, 3050
    Australia

    Site Not Available

  • Charité - Universitätsmedizin Berlin

    Berlin, 10117
    Germany

    Site Not Available

  • OVID Clinic, Augmented Psychotherapy

    Berlin, 10247
    Germany

    Site Not Available

  • Department of Psychiatry, University Hospital Frankfurt

    Frankfurt am Main, 60528
    Germany

    Site Not Available

  • Central Institute of Mental Health, Dept. of Molecular Neuroimaging

    Mannheim, 68159
    Germany

    Site Not Available

  • Universitätsklinik für Psychiatrie und Psychotherapie, Calwerstr. 14

    Tubingen, 72076
    Germany

    Site Not Available

  • Centrum Badań Klinicznych PI-House sp. z o.o.

    Gdansk, 80-546
    Poland

    Site Not Available

  • Department of Psychiatry, UCK

    Gdansk, 80-214
    Poland

    Site Not Available

  • UCK

    Gdansk, 80-214
    Poland

    Active - Recruiting

  • SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi

    Lodz, 92-216
    Poland

    Site Not Available

  • Klinika Inventiva

    Tuszyn, 95-080
    Poland

    Site Not Available

  • Department of Pharmacology and Physiology of CNS

    Warsaw, 02-957
    Poland

    Site Not Available

  • Hospital Clinic de Barcelona, Psychiatry and Psychology Dept.

    Barcelona, 08036
    Spain

    Site Not Available

  • Hospital del Mar

    Barcelona, 08003
    Spain

    Site Not Available

  • Parc Sanitari Sant Joan de Deu HD Numancia

    Barcelona, 08029
    Spain

    Site Not Available

  • Fundación de Investigación HM Hospital

    Madrid, 28050
    Spain

    Site Not Available

  • Centro de Salud Mental La Corredoria

    Oviedo, 33011
    Spain

    Site Not Available

  • Centro Salud San Juan

    Salamanca, 37005
    Spain

    Site Not Available

  • NIHR Exeter Clinical Research Facility

    Exeter, EX2 5DW
    United Kingdom

    Site Not Available

  • Clerkenwell Health

    London, W1G 8DR
    United Kingdom

    Site Not Available

  • King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN) - Centre for Affective Disorders (CfAD)

    London, SE5 8AF
    United Kingdom

    Site Not Available

  • UAB School of Public Health, Department of Health Behavior

    Birmingham, Alabama 35209
    United States

    Site Not Available

  • Woodland Research Northwest

    Rogers, Arkansas 72758
    United States

    Site Not Available

  • Kadima Neuropsychiatry Institute

    San Diego, California 92037
    United States

    Site Not Available

  • San Francisco Insight and Integration Center

    San Francisco, California 94114
    United States

    Site Not Available

  • Pacific Neuroscience Institute, Treatment and Research in Psychedelics (TRIP) Program

    Santa Monica, California 90404
    United States

    Site Not Available

  • Wholeness Center

    Fort Collins, Colorado 80525
    United States

    Site Not Available

  • Segal Trials Center for Psychedelic and Cannabis Research

    Lauderhill, Florida 33319
    United States

    Site Not Available

  • CenExel ACMR

    Atlanta, Georgia 30331
    United States

    Site Not Available

  • Emory University, Brain Health Center, Department of Psychiatry and Behavioral Sciences

    Atlanta, Georgia 30329
    United States

    Site Not Available

  • CenExel iResearch

    Decatur, Georgia 30030
    United States

    Site Not Available

  • Sunstone Medical PC (Sunstone Therapies / Aquilino Cancer Center)

    Rockville, Maryland 20850
    United States

    Site Not Available

  • Boston Clinical Trials

    Boston, Massachusetts 02131
    United States

    Site Not Available

  • CenExel HRI

    Berlin, New Jersey 08009
    United States

    Site Not Available

  • New York State Psychiatric Institute

    New York, New York 10032
    United States

    Site Not Available

  • Portland Psychotherapy

    Portland, Oregon 97227
    United States

    Site Not Available

  • Insite clinical research

    DeSoto, Texas 75115
    United States

    Site Not Available

  • AIM Trials

    Plano, Texas 75093
    United States

    Site Not Available

  • AIMS Trials

    Plano, Texas 75093
    United States

    Active - Recruiting

  • Cedar Clinical Research

    Draper, Utah 84020
    United States

    Site Not Available

  • University of Wisconsin, Dept of Family Medicine & Community Health

    Madison, Wisconsin 53705
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.